There are over 7,000 rare diseases that collectively affect more than 30 million Americans. Children and families struggling with these diseases need treatments — and hope. We're urging the U.S. Food and Drug Administration to use regulatory tools, such as its accelerated approval pathway, to speed up the development and approval of treatments.
But to date, FDA regulators haven't done so, even for promising drug candidates.
